Total Arch Replacement With Frozen Elephant Trunk Versus Hemiarch Replacement in the Management of Acute Type A Aortic Dissection
Key facts
- Who runs it
- Chinese University of Hong Kong
- Where
- Austria, Hong Kong, and Thailand3 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 150 people, planned
- Started
- Oct 2026
- Expected to end
- Oct 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Conventional hemiarch replacement
- E-vita® Open Neo; Artivion
- Thoraflex Hybrid; Terumo
- Record updated
- 18 March 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patient 's age is between 18 and 80 years
- Patient is willing and able to give informed consent
- Patient has acute type A aortic dissection with entry tear beyond ascending aorta
- Patient not in coma/irreversible end organ failure/cardiac massage for resuscitation
Who cannot take part
- Patient has co-morbidity (i.e. active malignancy (progressive, stable or partial remission)) causing expected survival to be less than 2 years
- There is no identifiable entry tear in the aorta
- The ascending entry tear extends into aortic arch
- Patient has entry tear only in ascending aorta
- Patient with Type B aortic dissection
- Patient has any other medical, social, or psychological problems, that in the opinion of the investigator, preclude the patient from participating in this study
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where is this trial?
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Acute Type A aortic dissection (ATAAD) and its complications are life-threatening conditions that cause more than 1400 hospital admissions and 300 deaths every year in Hong Kong and cause 172,927 deaths globally in 2019. There is an increasing trend in recent years.
Read full original descriptionShow less
Given the hyperacute presentation and complexity of the clinical manifestation with various mal-perfusion syndromes, the mortality of ATAAD remained high in all international reported registries and published series.
Conventional Hemiarch (HAR) replacement has been the gold standard procedure for ATAAD in most of cardiac surgical centers around the world because of the relative simplicity of the procedure. However, around 50-70% of patients were reported to develop distal anastomosis new entry after hemiarch procedure and for those with entry tear over aortic arch and distal mal-perfusion, hemiarch alone might not be able to solve the downstream problem. On the other hand, total arch replacement and frozen elephant trunk procedure (TARFET) is more complex, technically demanding procedure that could potentially cover/resect the arch entry tear and exclude tear over proximal descending thoracic aorta and, hence, solve the distal mal-perfusion syndrome. To date, there is no randomized control trial to answer whether HAR or TARFET procedure is superior in patients with ATAAD and entry tear is over the aortic arch or proximal descending thoracic aorta.
We plan to conduct a multi-center trial to recruit consecutive patients with ATAAD with entry tear beyond ascending aorta and randomized them, after informed consent, into either the conventional hemiarch replacement group (HAR) or total arch replacement and frozen elephant trunk (TARFET). The participating centers will collect pre- operative, intra-operative and post-operative clinical parameters for two groups of patients via REDCap system. Written informed consent, specifically allowing the use of clinical records for this randomized study, will be obtained from every patient prior to data collection. The primary outcome is the 30-day mortality of the ATAAD patients with surgically treated by HAR versus TARFET approach. The secondary outcomes are the major adverse cardiovascular and cerebral events, post-op renal replacement therapy, re-exploration for bleeding and re-intervention within 30-days.
This study will be the world's first multi-center randomized control trial in ATAAD to compare the 30-day mortality of patients treated with HAR and TARFET. It could be a guideline-changing study for the treatment of ATAAD and its impact on the surgical approach to patients suffering from ATAAD.
The 2 groups in the trial
- Conventional Hemiarch group (HAR)Existing treatment, for comparison
Under general anesthesia and transesophageal echocardiogram monitoring, a median sternotomy will be performed. Patients will be placed on cardiopulmonary bypass using arterial inflow from the femoral artery, axillary artery, or direct aortic cannulation, along with right atrial appendage venous cannulation. Systemic cooling to 25 degrees Celsius will commence, followed by thiopental coma and circulatory arrest. The aorta will be trimmed to the distal ascending aorta or proximal arch, and antegrade cerebral perfusion will be initiated to the brachiocephalic branch. The distal anastomosis will connect a vascular graft to the distal ascending aorta or aortic arch. After completing this, systemic perfusion and rewarming will begin, followed by the proximal anastomosis with the vascular graft. After de-airing, the aorta will be de-clamped, and the patient will be weaned from cardiopulmonary bypass and decannulated. Hemostasis and sternal closure will follow standard institutional protocols
Treatment: Conventional hemiarch replacement
- Total Arch Replacement and Frozen Elephant Trunk group (TARFET)Existing treatment, for comparison
Under general anesthesia and transesophageal echocardiogram monitoring, a median sternotomy will be performed. Patients will be placed on cardiopulmonary bypass via femoral, axillary, or direct aortic cannulation. Systemic cooling to 25 degrees Celsius will lead to thiopental coma and circulatory arrest. The aorta will be trimmed to the distal arch, with antegrade cerebral perfusion initiated. Distal anastomosis will connect a vascular graft to the distal arch, followed by visceral perfusion, rewarming, and proximal anastomosis. After de-airing, the aorta will be de-clamped, and the patient will be weaned from bypass and decannulated. Hemostasis and sternal closure will follow standard protocols. Arterial cannulation sites for HAR and TARFET will be determined by the surgeon based on the clinical scenario.
Treatment: E-vita® Open Neo; Artivion and Thoraflex Hybrid; Terumo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Control Trial of Total Arch Replacement With Frozen Elephant Trunk Versus Conventional Hemiarch Replacement in Patients With Acute Type A Aortic Dissection (TARFET-TAAD)
- Criteria questions
- Built from NCT06676371, who can take part
- Record updated
- 18 March 2026